M6620 First in Human Study
Completed
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2020
Locations: US Oncology - Texas Oncology-Midtown - Austin Midtown, Austin, Texas +3 locations
Conditions: Advanced Solid Tumor
Treatment of Tumors of the Choroid Plexus Epithelium
Terminated
The goal of this clinical research study is to compare carboplatin to cyclophosphamide when given with etoposide, vincristine, and radiation therapy in the treatment of choroid plexus tumors. The safety of these 2 combination therapies will also be compared. Objectives: OVERALL AIM: To improve choroid plexus tumor treatment through better understanding of the tumor biology and through increased knowledge about the benefit of specific treatment elements. Specific Objectives: The study will h... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/21/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Choroid Plexus Tumors
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Completed
This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without docetaxel) or atezolizumab and trastuzumab emtansine in participants with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) and locally advanced early breast cancer (EBC), and atezolizumab with doxorubicin and cyclophosphamide in HER2-n... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2020
Locations: MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Completed
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2020
Locations: Mary Crowley Cancer Research Center - Medical City, Dallas, Texas +3 locations
Conditions: Advanced Cancer, Advanced Malignancies
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Completed
The goal of this clinical research study is to find out if erlotinib given with chemotherapy and radiation therapy can help to control NSCLC. The safety of this combination treatment will also be studied. Researchers will also test the tissue from your earlier biopsy to measure the levels of epidermal growth factor receptor (EGFR). The purpose of EGFR testing is to learn about any link between various forms of EGFR and your response to treatment with erlotinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Non-Small Cell Lung Cancer, Lung Cancer
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
Terminated
This phase II trial is studying how well giving bortezomib together with carboplatin works in treating patients with metastatic pancreatic cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with carboplatin may kill more tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2019
Locations: MD Anderson Cancer Network, Houston, Texas
Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Terminated
The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly and every 3-weeks ABI-007 in combination with carboplatin (area under the curve \[AUC\]=6) in patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/16/2019
Locations: University of Texas, MD Anderson Cancer Center, Houston, Texas
Conditions: Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
A Study in Advanced Solid Tumors
Completed
The primary purpose of this study is to help answer the following research question(s): * To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with carboplatin \[pharmacokinetic (PK) analysis\] * To see if any drug interactions occur between cetuximab and carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Completed
This phase II trial studies how well temsirolimus, carboplatin, and paclitaxel as first-line therapy works in treating patients with newly diagnosed stage III-IV clear cell ovarian cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus wi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/06/2019
Locations: M D Anderson Cancer Center CCOP Research Base, Houston, Texas +1 locations
Conditions: Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Terminated
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, and carboplatin, work in d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2019
Locations: The Don and Sybil Harrington Cancer Center, Amarillo, Texas +3 locations
Conditions: Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Terminated
This is a "tissue banking and data review" research study that also has a "clinical" research part: * The goal of the tissue banking part of this study is to store tissue in a research tissue bank by the International Society for Pediatric Oncology (SIOP) at an international reference center for choroid plexus tumors. The tissue will be used in future research related to cancer. * The goal of the data review part of this study is to collect information from the medical records of patients with... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/01/2019
Locations: Children's Cancer Hospital at UT MD Anderson Cancer Center, Houston, Texas
Conditions: Brain Cancer, Choroid Plexus Tumors
Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
Completed
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase II trial to determine the effectiveness of specialized radiation therapy either alone or after chemotherapy a... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/24/2019
Locations: Texas Tech University Health Sciences Center School of Medicine - Amarillo, Amarillo, Texas +10 locations
Conditions: Brain Tumor, Central Nervous System Tumor